Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 4/20 | 0.44 |
| ▸ | CCND1 | P24385 | 4/20 | 0.44 |
| ▸ | ASH1L | Q9NR48 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364970 | 1.00 | PLAU (0.48) | PLAUPLGPRKCICDK4CCND1 | |
| SCHEMBL18491374 | 0.80 | PRKCI (0.49) | PLAUPLGPRKCIEGFRNTSR1 | |
| SCHEMBL26070030 | 0.79 | PLG (0.47) | PLAUPLGCDK4CCND1ASH1L | |
| SCHEMBL31312599 | 0.79 | PRKCI (0.53) | PLAUPLGPRKCICDK4CCND1 | |
| SCHEMBL5089820 | 0.78 | PRKCI (0.56) | PLAUPLGPRKCICDK4CCND1 | |
| SCHEMBL16370787 | 0.78 | PRKCI (0.55) | PLAUPLGPRKCICDK4CCND1 | |
| SCHEMBL30672832 | 0.78 | PRKCI (0.55) | PLAUPLGPRKCICDK4CCND1 | |
| SCHEMBL30364948 | 0.77 | PRKCI (0.44) | PLAUPLGPRKCICDK4CCND1 | |
| SCHEMBL23902734 | 0.77 | PRKCI (0.44) | PLAUPLGPRKCICDK4CCND1 | |
| SCHEMBL6789563 | 0.76 | PRKCI (0.56) | PLAUPLGPRKCICDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4132907-B1 | (1H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI SA (FR) | 2024-04-24 | — | — | EP | disclosed |
| US-20230140808-A1 | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer | SANOFI (FR) | 2023-05-04 | — | — | US | disclosed |
| EP-4132907-A1 | (1 H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2023-02-15 | — | — | EP | disclosed |
| CN-115667216-A | (1H-indol-5-yl) acrylamide derivatives as TEAD proteins and inhibitors of the HIPPO-YAP1/TAZ signaling cascade for the treatment of cancer | 赛诺菲 | 2023-01-31 | — | — | CN | disclosed |
| EP-3892614-A1 | (1H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2021-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140808-A1 | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer | YAP1, YES1, TEAD1 | PLAU 4697/4885PLG 4437/4885PRKCI 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.